ライフサイエンスコーパス: cancer of the breast

1 reduce the risk of human cancers, including cancer of the breast.

2 rized by hamartomas and by predisposition to cancer of the breast and thyroid.

3 CA1 or BRCA2 strongly predispose carriers to cancers of the breast and other organs.

4 les, is under study as a preventive agent of cancers of the breast and other organs.

5 mutation is observed frequently in sporadic cancers of the breast and other sites, although little i

6 We investigate the familial risks of cancers of the breast and ovary, using data pooled from

7 evelopment and is associated with epithelial cancers of the breast and ovary.

8 sed survival was highest among subjects with cancers of the breast and prostate, although the effects

9 across many tumor types, including advanced cancers of the breast and prostate.

10 r ataxia type 1 and as a tumor suppressor in cancers of the breast and prostate.

11 ntraceptives and elucidating the etiology of cancers of the breast and reproductive tract.

12 No significant association was seen with cancer of the breast, colon, prostate, or leukemia.

13 diagnosis offers clear benefit (melanoma and cancers of the breast, colon, and lung).

14 cts in several human malignancies, including cancers of the breast, colon, and prostate, the mechanis

15 s of different histogenetic types, including cancers of the breast, colon, lung, esophagus, skin, lym

16 this locus represent a major risk factor for cancers of the breast, colorectum, and bladder, and it w

17 or OS remained significant for patients with cancers of the breast, colorectum, and prostate after ex

18 A central epidemiological feature of cancers of the breast, endometrium and ovary is the shar

19 for obesity-related malignancies, including cancers of the breast, endometrium, colon, and prostate.

20 nificant associations were also observed for cancers of the breast, endometrium, lung, kidney, upper

21 Patients with cancers of the breast (hazard ratio [HR], 1.70; P < .001

22 survival was also inferior for patients with cancers of the breast (HR, 1.41; P = .005) and colorectu

23 lymph nodes (SLNs) from a woman with lobular cancer of the breast is frequently challenging.

24 n situ (DCIS) to infiltrating and metastatic cancer of the breast is thought to be a consequence of c

25 an cause most forms of cancer, leukaemia and cancers of the breast, lung and thyroid being particular

26 Paclitaxel has activity against cancers of the breast, lung, prostate, cervix, and ovary

27 The study population included persons with cancer of the breast (n = 24), lung (n = 18), colon (n =

28 ritoneal cavity of 18 patients with advanced cancer of the breast (n = 6) or ovary (n = 12).

29 All patients with cancers of the breast (n = 579,164), colorectum (n = 412

30 A family history of cancer of the breast, ovary, colorectum, or prostate in

31 be missed unless a careful family history of cancer of the breast, ovary, or several integrally assoc

32 onferred by BRCA1 and BRCA2 in women are for cancers of the breast, ovary, fallopian tube, and perito

33 GHRH and its mRNA are also found in human cancers of the breast, ovary, prostate, lung, and other

34 ignant precursor lesions, including those of cancers of the breast, pancreas, and prostate, and is as

35 CSCs in many tumors--including cancers of the breast, pancreas, head and neck, colon, s

36 Similarities with cancer of the breast, prostate, lung, and other sites ra

37 y activities and acts as a growth factor for cancers of the breast, prostate and tissues of the femal

38 (95% CI: 0.67, 0.94), and the subgroups for cancers of the breast, prostate, colon and rectum, lung,

39 d risk of cancer recurrence and mortality in cancers of the breast, prostate, colon and, perhaps, oth

40 Cancers of the breast, uterine cervix, and lip or oral c

41 igher risk of cancer-specific death only for cancer of the breast, uterus, or bladder.

42 omach and prostate in men and for death from cancers of the breast, uterus, cervix, and ovary in wome

43 pregnant patients with primary or recurrent cancer of the breast were managed by outpatient chemothe

44 s) diagnosed with a first, primary, invasive cancer of the breast (women), colon, rectum, or prostate